Last edition
News about "Trodelvy"
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
Trodelvy | 26/06/2026 | By News Bureau | 177
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
Trodelvy | 26/06/2026 | By News Bureau | 177
The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.
Trodelvy | 25/06/2026 | By News Bureau
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Trodelvy | 22/05/2026 | By News Bureau | 511
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy